Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilavonemab in Progressive Supranuclear Palsy
NCT02985879Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Dec 2016
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of tilavonemab in progressive supranuclear palsy (PSP) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Progressive Supranuclear Palsy Rating Scale Total Score at 52 weeks and Number of Participants With Adverse Events up to 80 weeks. Started Dec 2016; status: terminated.
02
Drugs
tilavonemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT02985879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985879.